Patheon to host strategy seminar for emerging companies

Published: 5-Mar-2015

Experts will provide attendees with key strategies for API development


Industry-leading experts will discuss key strategies for early product development at a seminar this month hosted by Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors.

The event 'API Supply: Key Strategies for Creating Value in Early-Stage Development', which looks to address challenges in API development and drug formulation for emerging companies will be held on Thursday 19 March at the Embassy Suites Airport-Waterfront in San Francisco from 11.30am to 3.30pm. Experts will provide attendees with key strategies for API development.

Presentations include:

  • Rapid Path to First-time-in-Humans: An Example of Expedited Chemical Development by Sriram Naganathan, Ph.D., senior director, chemical development at Dermira, presenting an example of expedited chemical development of a kinase inhibitor toward enabling first-in-human clinical studies.
  • API Continuous Process Considerations by Peter Poechlauer, Ph.D., innovation manager, Patheon, highlighting scalability as a key factor for product development.
  • How IP Decisions Can Add Value by Bernie Brown, Ph.D., patent attorney, Womble Carlyle Sandridge & Rice, sharing insights on how to add product value based on key intellectual property decisions, and discuss the importance of early-stage patents, as well as tips on developing an IP strategy that provides commercially relevant coverage and value throughout the drug life cycle.

For more information and to register, please visit http://info.patheon.com/api-supply-key-strategies.

  • Companies:
  • Patheon
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

Read more
In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
Manufacturing

Financial gains for choosing a single-source outsourcing partner

Tufts Center for Drug Development study shows that there are multimillion-dollar benefits of using single-source pharma drug development and manufacturing model
Design & Build

Patheon to invest $45m to support continued growth

Investments by the pharmaceutical solutions provider include facility and equipment expansions in key service areas to meet growing customer demand
Manufacturing

Anticipating the formulation challenges of complex molecules

Patheon's webinar which took place on 28 June, is now available on demand
Regulatory

Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
Manufacturing

Patheon completes sterile expansion at Greenville site

Company invests $26m in sterile Pharmaceutical Development Services suite
Subscribe now